GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Short Percentage of Float

Kaken Pharmaceutical Co (TSE:4521) Short Percentage of Float


View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Kaken Pharmaceutical Co's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Short Percentage of Float falls into.



Kaken Pharmaceutical Co (TSE:4521) Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines